Skip to main content
53°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Relay Therapeutics, Inc. - Common Stock
(NQ:
RLAY
)
2.690
+0.080 (+3.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Relay Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
October 12, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
September 19, 2023
During Tuesday's session, 275 companies made new 52-week lows.
Via
Benzinga
Earnings Outlook For Relay Therapeutics
August 07, 2023
Via
Benzinga
11 Analysts Have This to Say About Relay Therapeutics
June 09, 2023
Via
Benzinga
Relay Therapeutics: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 26, 2023
On Tuesday, 386 stocks made new 52-week lows.
Via
Benzinga
Earnings Outlook For Relay Therapeutics
May 03, 2023
Via
Benzinga
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 18, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
September 07, 2023
On Thursday, 283 companies set new 52-week lows.
Via
Benzinga
What 11 Analyst Ratings Have To Say About Relay Therapeutics
April 20, 2023
Via
Benzinga
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 08, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
August 01, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
InMode, Daktronics, Domino's Pizza And Other Big Stocks Moving Higher On Wednesday
July 12, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
May 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END
Via
FinancialNewsMedia
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
May 25, 2023
Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported results
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
May 24, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
May 04, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
April 27, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
April 27, 2023
Evogene employs an artificial intelligence platform for decoding plant phenotypes and microbial genomes. Consider its' research agenda, applications, and at-the-market products. The set-up may present...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
April 20, 2023
Via
Benzinga
Why Relay Therapeutics Stock Is Trading Higher Today
April 19, 2023
Relay Therapeutics (NASDAQ: RLAY) shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy and announced a $29 price target. Also, the stock is rebounding...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
April 19, 2023
Via
Benzinga
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
April 19, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 18, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
April 18, 2023
On Tuesday, 91 stocks hit new 52-week lows.
Via
Benzinga
Why Relay Therapeutics Stock Is Plunging Today
April 18, 2023
Relay Therapeutics Inc (NASDAQ: RLAY) announced initial clinical data for RLY-2608, an investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα.
Via
Benzinga
Ericsson, Johnson & Johnson, Goldman Sachs And Other Big Stocks Moving Lower On Tuesday
April 18, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 18, 2023
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional...
Via
Benzinga
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
April 18, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says
April 13, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.